A single-arm phase II study evaluating the efficacy of osimertinib plus LAT in EGFR-mutated NSCLC patients with synchronous oligometastatic disease is currently ongoing (NCT04908956). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.